AusperBio Raises $120M to Advance Next-Gen HBV Therapies

SAN FRANCISCO, Aug 27, 2026

$120 Million Financing Supports Phase 3 Development

The Series C financing was led by a strategic investor and included participation from new investor RA Capital Management, together with continued backing from existing investors including HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments. AusperBio said the financing reflects continued investor confidence in its lead programs and differentiated oligonucleotide technology platforms. A significant portion of the proceeds will support AHB-137, the company’s lead investigational antisense oligonucleotide (ASO) therapy for CHB, as it progresses through its Phase 3 registrational program in China. The funding will also support commercialization readiness, positioning the company for potential future market entry if the candidate successfully completes development and receives regulatory approval. AHB-137 remains an investigational product and has not been approved by any regulatory authority.

AHB-137 Targets Functional Cure of Hepatitis B

AHB-137 is being developed using AusperBio’s proprietary Med-Oligo™ ASO platform and is designed to address several biological mechanisms involved in chronic hepatitis B infection. According to the company, the candidate is intended to suppress hepatitis B surface antigen (HBsAg) production, inhibit viral DNA replication and promote immune reactivation, with the goal of achieving a functional cure for CHB. The candidate has completed a global Phase 1 study and multiple Phase 2 studies and is currently being evaluated in a Phase 3 trial in China. AusperBio is pursuing a coordinated global development strategy for AHB-137, with the new financing expected to help advance the program toward potential commercialization. The company believes the investigational therapy could serve as a backbone therapy within combination approaches designed to deliver deeper and more durable antiviral responses.

AHB-171 Expands Next-Generation HBV Pipeline

Beyond AHB-137, AusperBio plans to use the financing to accelerate AHB-171, an investigational hepatocyte-targeted small interfering RNA (siRNA) therapy for chronic hepatitis B. AHB-171 utilizes the company’s proprietary Au-HALO™ targeted delivery platform, which is designed to selectively deliver the therapeutic to liver cells and suppress viral gene expression. The company describes AHB-171 as its first clinical candidate developed using the Au-HALO platform and views the program as an important step in validating its targeted delivery and siRNA capabilities. AusperBio also plans to advance next-generation combination strategies aimed at functional cure of CHB while expanding its targeted oligonucleotide pipeline into additional diseases with significant unmet medical needs. Chronic hepatitis B remains a substantial global health challenge, with long-term infection associated with complications including cirrhosis and liver cancer. Current therapies can suppress viral replication but rarely achieve a functional cure, highlighting the need for new therapeutic approaches. With its latest financing, AusperBio is strengthening its clinical and commercial infrastructure while advancing multiple oligonucleotide modalities toward potentially more durable treatment options for patients with chronic hepatitis B.

Source: AusperBio press relese